OOIR: Observatory of International Research

Papers

(The TQCC of CTS-Clinical and Translational Science is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
COVID‐19 vaccine hesitancy: Race/ethnicity, trust, and fear	267
COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful?	125
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration	113
SARS‐CoV‐2 infection as a trigger of autoimmune response	105
Opportunities and challenges in translational science	78
Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation	54
First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor	52
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial	51
Biolink Model: A universal schema for knowledge graphs in clinical, biomedical, and translational science	50
Approval success rates of drug candidates based on target, action, modality, application, and their combinations	49
Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto’s thyroiditis: A prospective randomized‐controlled trial	40
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs	40
Digitally Enabled, Patient‐Centric Clinical Trials: Shifting the Drug Development Paradigm	40
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled,	38
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH	37
Human Induced Pluripotent Stem Cell Derived Sensory Neurons are Sensitive to the Neurotoxic Effects of Paclitaxel	35
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence	34
Artificial intelligence in pharmacology research and practice	32
Gene therapy for diabetic peripheral neuropathy: A randomized, placebo‐controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor	32
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction	32
Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events	30
A Strategy to Treat COVID‐19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study	30
Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single‐center, randomized, double‐blind, placebo‐controlled multiple‐ascending‐dose study	29
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)	29
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)	29

Drugs used for the treatment of cerebral and disseminated infections caused by free‐living amoebae	29
Artificial intelligence in rare disease diagnosis and treatment	27
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults	27
First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2	27
Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV	27
The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19	26
Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database	26
Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial	24
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19	23
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study	23
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19	23
Short‐ and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity – a non‐randomized three‐armed controlled trial	22
Progress toward a universal biomedical data translator	21
Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression:A randomized, double‐blind, placebo‐controlled trial	21
Antinuclear antibodies in COVID 19	21
Artificial intelligence in clinical and translational science: Successes, challenges and opportunities	20
Altered vitamin A metabolism in human liver slices corresponds to fibrogenesis	20
Role for Drug Transporters in Chemotherapy‐Induced Peripheral Neuropathy	20
Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials	20
Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson’s Disease	20
Remote FEV1 Monitoring in Asthma Patients: A Pilot Study	19
Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL	19
Diagnostic and prognostic capabilities of a biomarker and EMR‐based machine learning algorithm for sepsis	18
GSTP1andABCB1Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel‐Based Chemotherapy in Ovarian Cancer	18
Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials	18
Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults	18
Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis	18
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers	17
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies	17
Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population	17
Characterizing Pharmacogenetic Testing Among Children’s Hospitals	17
Reimagining the peer‐review system for translational health science journals	17
Pharmacokinetics of bempedoic acid in patients with renal impairment	16
Evaluation of moxifloxacin in canine and non‐human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration‐QTc analysis	16
Dose‐dependent inactivation of airway tryptase with a novel dissociating anti‐tryptase antibody (MTPS9579A) in healthy participants: A randomized trial	16
Evolving drug regulatory landscape in China: A clinical pharmacology perspective	16
Upadacitinib: Mechanism of action, clinical, and translational science	16
Advancing translational science education	16
Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers	16
Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality	16
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer	16
Microphysiological systems in absorption, distribution, metabolism, and elimination sciences	16
Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2	16
Facilitators and barriers to pediatric clinical trial recruitment and retention in rural and community settings: A scoping review of the literature	15
Autoantibodies in moderate and critical cases of COVID‐19	15
Preoperative medication use and development of postoperative delirium and cognitive dysfunction	15
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)	15
Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies	15
A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab	15
Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users	15

A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP‐458) in Healthy Adult Volunteers	15
SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma	15
Effect of cenobamate on the single‐dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects	15
Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach	15
The vaccine hesitancy continuum among hesitant adopters of the COVID‐19 vaccine	15
Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs	15
Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling	14
Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study	14
Recommended practices and ethical considerations for natural language processing‐assisted observational research: A scoping review	14
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy	14
HLA‐associated adverse drug reactions ‐ scoping review	14
Effects of vancomycin‐induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects	14
A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors	14
The economics of moonshots: Value in rare disease drug development	14
A population pharmacodynamic Markov mixed‐effects model for determining remimazolam‐induced sedation when co‐administered with fentanyl in procedural sedation	14
Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia	14
First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia	14
G970R‐CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect	14
Comparison of the influence of light between circularly polarized and linearly polarized smartphones on dry eye symptoms and asthenopia	14
Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic	14
A call to action: Issuing a diversity and inclusion challenge to research organizations	14
Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications	13
Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer	13
Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease	13
Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor	13
REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics	13
Integrating real‐world data to accelerate and guide drug development: A clinical pharmacology perspective	13
Genetics of drug‐induced liver injury: Current knowledge and future prospects	13
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development	13
Analysis of a large cohort of pancreatic cancer transcriptomic profiles to reveal the strongest prognostic factors	13
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator	13
First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers	13
Effects of 5‐HT_₃ receptor antagonists on cisplatin‐induced kidney injury	13
Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial	12
Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018	12
Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects	12
Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations – A nationwide trial	12
Design and conduct considerations for studies in patients with impaired renal function	12
First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects	12
Practical publication metrics for academics	12
Effects on the Ocular Surface from Reading on Different Smartphone Screens: A Prospective Randomized Controlled Study	12
Proton pump inhibitor use and risk of depression and anxiety in children: nationwide cohort study	12
Effect of inhaled corticosteroids on microbiome and microbial correlations in asthma over a 9‐month period	12
Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities	12
Hesitant adopters: An examination of hesitancy among adults in Arkansas who have taken the COVID‐19 vaccine	12
Identification of small molecules that mitigate vincristine‐induced neurotoxicity while sensitizing leukemia cells to vincristine	12
Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model‐informed precision dosing trial simulations	12
Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid‐resistant from glucocorticoid‐sensitive idiopathic nephrotic syndrome patients	12
Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects	12
Estimating peptide half‐life in serum from tunable, sequence‐related physicochemical properties	12
Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19	12
PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients	12
Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients	11
Sarcopenia in Patients With Normal Body Mass Index Is an Independent Predictor for Postoperative Complication and Long‐Term Survival in Gastric Cancer	11
Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies	11
Adherence to triple‐component antihypertensive regimens is higher with single‐pill than equivalent two‐pill regimens: A randomized controlled trial	11
Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development	11
Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators	11
Persistent follicular granulosa cell senescence and apoptosis induced by methotrexate leading to oocyte dysfunction and aberrant embryo development	11
An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites	11
Compassionate use of ruxolitinib in patients with SARS‐Cov‐2 infection not on mechanical ventilation: Short‐term effects on inflammation and ventilation	11
Adverse event profiles of epidermal growth factor receptor‐tyrosine kinase inhibitors in cancer patients: A systematic review and meta‐analysis	11
In vitro safety “clinical trial” of the cardiac liability of drug polytherapy	11
Controlled oxygenated rewarming as novel end‐ischemic therapy for cold stored liver grafts. A randomized controlled trial	10
Pharmacogenomic‐based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system	10
Assessing the impact of COVID‐19 on registered interventional clinical trials	10
A proof of concept using the Ussing chamber methodology to study pediatric intestinal drug transport and age‐dependent differences in absorption	10
Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants	10
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment	10
Emergency department admissions induced by drug–drug interactions in the elderly: A cross‐sectional study	10
Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID‐19: A Retrospective Multicenter Study in the United States	10
Managing endothelial dysfunction in COVID‐19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double‐blind, placebo‐controlled, randomized clini	10
Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity	10
Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N‐dimethyltryptamine – Implications for dose considerations	10
Association of UGT1A16, UGT1A128, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis	10
Type‐2 airway inflammation in mild asthma patients with high blood eosinophils and high fractional exhaled nitric oxide	10
High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation	10
Predicting citation impact from altmetric attention in clinical and translational research: Do big splashes lead to ripple effects?	10
Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects	10
Metabolomics analysis of the serum from children with urolithiasis using UPLC‐MS	10

Pharmacometabolomics identifies candidate predictor metabolites of an L‐carnitine treatment mortality benefit in septic shock	10
Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat	10
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes	10
Fear and food: Anxiety‐like behavior and the susceptibility to weight loss in an activity‐based anorexia rat model	10
Quantitative protein expression of blood‐brain barrier transporters in the vasculature of brain metastases of patients with lung and breast cancer	10
Effect of Crohn’s Disease on Villous Length and CYP3A4 Expression in the Pediatric Small Intestine	10
Estimation of glomerular filtration rate for drug dosing in patients with very high or low body mass index	10
Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants	10
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria	10
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults	9
Potential benefit of vitamin D supplementation in people with respiratory illnesses, during the COVID‐19 pandemic	9
Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease	9
Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phaseIIrelapsing multiple sclerosis study	9
Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects	9
Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals	9
First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor	9
Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science	9
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers	9
A permeability‐ and perfusion‐based PBPK model for improved prediction of concentration‐time profiles	9
A metabolomic analysis of thiol response for standard and modified N‐acetyl cysteine treatment regimens in patients with acetaminophen overdose	9
Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial	9
An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma	9
Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk	9
Real‐world evidence of population differences in allopurinol‐related severe cutaneous adverse reactions in East Asians: A population‐based cohort study	9
Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta‐analysis	9
Optimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modeling	9
An untargeted metabolomics analysis of exogenous chemicals in human milk and transfer to the infant	9
Factors related to polypharmacy and hyper‐polypharmacy for the elderly: A nationwide cohort study using National Health Insurance data in South Korea	9
Hybrid physiologically‐based pharmacokinetic model for remdesivir: Application to SARS‐CoV‐2	9
Prospective evaluation of high‐dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function	9
Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics	9
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat	9
Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)	9
Impact of NFIB and CYP1A variants on clozapine serum concentration—A retrospective naturalistic cohort study on 526 patients with known smoking habits	9
Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS‐441524 in patients with COVID‐19: A limited case series	9
Hydroxychloroquine for treatment of non‐hospitalized adults with COVID‐19: A meta‐analysis of individual participant data of randomized trials	9
Design and conduct considerations for studies in patients with hepatic impairment	9
Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis	9
Tutorial: Statistical analysis and reporting of clinical pharmacokinetic studies	9
Pharmacogenetic variants and risk of remdesivir‐associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID‐19	8
Atorvastatin population pharmacokinetics in a real‐life setting: Influence of genetic polymorphisms and association with clinical response	8
A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients	8
Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial	8
BLOODPAC: Collaborating to chart a path towards blood‐based screening for early cancer detection	8
Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes	8
Pharmacogenomic landscape of Indian population using whole genomes	8
Remimazolam versus propofol in combination with esketamine for surgical abortion: A double‐blind randomized controlled trial	8
Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended‐release tacrolimus preparation	8
Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targetingCYP3A4*1Gallele function	8
Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents	8
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2	8
Contextualizing single‐arm trials with real‐world data: An emulated target trial comparing therapies for neovascular age‐related macular degeneration	8
A phase I, randomized, placebo‐controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID‐19	8
Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID‐19: A simulation study	8
Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies	8
Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing	8
Altered mitochondrial metabolism in peripheral blood cells from patients with inborn errors of β‐oxidation	8
Are body surface area based estimates of liver volume applicable to children with overweight or obesity? An in vivo validation study	8
Umbilical cord blood–derived exosomes from healthy term pregnancies protect against hyperoxia‐induced lung injury in mice	8
Is this the end for ranitidine? NDMA presence continues to confound	8
Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies	8
Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval	8
Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta‐Analysis	7
Hydrogen sulfide donor protects against mechanical ventilation‐induced atrophy and contractile dysfunction in the rat diaphragm	7
Non‐synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban	7
Functional characterization of novel rare CYP2A6 variants and potential implications for clinical outcomes	7
Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies	7
Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children	7
Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5	7
CYP2C83 and 4 define CYP2C8 phenotype: An approach with the substrate cinitapride	7
Dexamethasone exposure in normal‐weight and obese hospitalized COVID‐19 patients: An observational exploratory trial	7
Outreach to new mothers through direct mail and email: recruitment in the Early Check research study	7
Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study	7
A phase I, randomized, double‐blind, placebo‐controlled, single‐ and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX‐128, a highly selective Na_v<	7
Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines	7
Genomewide association analysis of warfarin dose requirements in Middle Eastern and North African populations	7
Sex, racial, and ethnic diversity in clinical trials	7
Peppermint oil effects on the gut microbiome in children with functional abdominal pain	7
Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele	7
The relationship between high density lipoprotein cholesterol and sepsis: A clinical and genetic approach	7
Strategic, feasibility, economic, and cultural aspects of phase 0 approaches	7
Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies	7
Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)	7
Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants	7
DNA methyltransferase inhibitor exposure–response: Challenges and opportunities	7
Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs	7
High mobility group box 1, ATP, lipid mediators, and tissue factor are elevated in COVID‐19 patients: HMGB1 as a biomarker of worst prognosis	7
Incidence of complications from indwelling pleural catheter for pleural effusion: A meta‐analysis	7
Computational models in inflammatory bowel disease	7
Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end‐stage renal disease	7
Tyrosine Kinase Inhibitors Reduce Glucose Uptake by Binding to an Exofacial Site on hGLUT‐1: Influence on ¹⁸F‐FDG PET Uptake	7
Relationship of hemoglobin level and plasma coproporphyrin‐I concentrations as an endogenous probe for phenotyping OATP1B	6
Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan	6
TXNDC12 knockdown promotes ferroptosis by modulating SLC7A11 expression in glioma	6
How can real‐world evidence aid decision making during the life cycle of nonprescription medicines?	6